EORTC-1219/DAHANCA-29试验的放疗质量保证:病例个体化审查分析
该研究对EORTC-1219/DAHANCA-29随机试验中194例局部晚期头颈癌患者的放疗计划进行中心审查,比较前瞻性个体化病例审查(p-ICR)与回顾性审查(r-ICR)对方案依从性和计划质量的影响。结果显示p-ICR使CTV勾画可接受率从首次提交的69%提升至最终审查的93%,且p-ICR接受率(90%)高于r-ICR(73%),剂量与计划可接受率在首次和最终提交均保持97%。
要点
- p-ICR使CTV勾画可接受率从首次提交的69%改善至最终审查的93%。
- p-ICR的接受率(90%)比r-ICR(73%)高18%。
- 剂量与计划可接受率在首次和最终提交均为97%,p-ICR与r-ICR差异极小。
核心结论
- p-ICR显著改善了CTV勾画质量,确保了更高的方案依从性和治疗计划准确性。
- 建议对复杂治疗采用p-ICR,并根据各中心的表现进行调整。
研究设计与样本
- 十九个中心提交放疗计划进行中心审查,试验要求每个机构前5例患者进行前瞻性ICR(p-ICR),后续计划回顾性审查或可选p-ICR。
- 计划由放射肿瘤科医生和医学物理师审查,p-ICR中不可接受的计划重新提交审查,而回顾性ICR(r-ICR)病例仅审查一次。
- 共审查所有194例随机患者的放疗计划,包括174次p-ICR和44次r-ICR。
主要发现
- p-ICR的勾画可接受率从首次提交的69%提高至最终审查的93%。
- p-ICR的接受率(90%)比r-ICR(73%)高18%。
- 剂量和计划可接受率在首次和最终提交均保持97%,p-ICR与r-ICR之间差异极小。
关键数值与推荐
- 计划分类为「符合方案可接受」、「可接受变异」或「不可接受变异」。
临床怎么用
- 对复杂头颈癌放疗采用前瞻性个体化病例审查以提高勾画质量和方案依从性。
- 根据各中心表现调整p-ICR策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EORTC-1219/DAHANCA-29 trial investigated whether adding nimorazole to accelerated radiotherapy (RT) and chemotherapy improves locoregional control of locally advanced head and neck cancer. As part of the trial's RT quality assurance (RTQA) program, individual case review (ICR) of RT plans was performed to assess protocol compliance and treatment planning quality. MATERIALS AND METHODS: Nineteen centers submitted RT plans for central review. The trial mandated prospective ICR (p-ICR) for the first five patients per institution, with subsequent plans reviewed retrospectively or as optional p-ICR. Plans were reviewed by radiation oncologists and medical physicists. Plans deemed unacceptable in p-ICR were resubmitted for review, whereas retrospective ICR (r-ICR) cases were reviewed once. Plans were categorized as "Acceptable as per protocol," "Acceptable variation," or "Unacceptable variation.". RESULTS: RT plans for all 194 randomized patients were reviewed, with 174p-ICRs and 44 r-ICRs. The delineation acceptability rate for p-ICR improved from 69% at the first submission to 93% at final review. p-ICR had an 18% higher acceptance rate (90%) compared to r-ICR (73%). Dose and plan acceptability remained high (97%) at both first and final submission, with minimal differences between p-ICR and r-ICR. CONCLUSION: P-ICR significantly improved CTV delineation quality, ensuring higher protocol compliance and treatment planning accuracy. p-ICRs are recommended for complex treatments, tailored to the performance of individual sites.
引用
- Alyamani N, Abrunhosa-Branquinho A, Corning C, et al. Radiotherapy quality assurance of the prospective randomised EORTC-1219/DAHANCA-29 trial: an individual case review analysis. Radiother Oncol. 2025. PMID: 40987385. doi:10.1016/j.radonc.2025.111141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。